Obesity is directly associated with an increased risk of developing CKD, regardless of other comorbid conditions. Although the molecular mechanisms that link both diseases are not well established, the role of adipose tissue (AT) is becoming increasingly important in obesity-associated kidney damage. In the context of obesity, lipotoxicity and the alteration of AT secretion profile promote inflammation, oxidative stress, and fibrosis in the kidney, which ultimately leads to impaired renal function. Different studies have highlighted the importance of body weight loss in the improvement of renal function markers. In this regard, bariatric surgery, rather than low-calorie diets, has been accepted as the most effective option to lose weight. In fact, a significant reduction in proteinuria and hyperfiltration has been observed in association with surgically induced weight loss. Detection of early signs of kidney dysfunction in patients with obesity has not been accomplished yet, though. Therefore, understanding the harmful effects within the adipo-renal axis is essential to prevent the progression to the irreversible renal insufficiency. MicroRNAs have recently been described as important modulators of normal kidney function. Some of these microRNAs could be potential early markers of kidney damage, which would help with the diagnosis and the prevention of CKD.

1.
Ejerblad
E
,
Fored
CM
,
Lindblad
P
,
Fryzek
J
,
McLaughlin
JK
,
Nyrén
O
.
Obesity and risk for chronic renal failure
.
J Am Soc Nephrol
.
2006
;
17
(
6
):
1695
702
. .
2.
D'Agati
VD
,
Chagnac
A
,
de Vries
AP
,
Levi
M
,
Porrini
E
,
Herman-Edelstein
M
,
Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis
.
Nat Rev Nephrol
.
2016
;
12
(
8
):
453
71
. .
3.
Hashimoto
Y
,
Tanaka
M
,
Okada
H
,
Senmaru
T
,
Hamaguchi
M
,
Asano
M
,
Metabolically healthy obesity and risk of incident CKD
.
Clin J Am Soc Nephrol
.
2015
;
10
(
4
):
578
83
. .
4.
Zhu
Q
,
Scherer
PE
.
Immunologic and endocrine functions of adipose tissue: implications for kidney disease
.
Nat Rev Nephrol
.
2018
;
14
(
2
):
105
20
. .
5.
Martinez-Garcia
C
,
Izquierdo-Lahuerta
A
,
Vivas
Y
,
Velasco
I
,
Yeo
TK
,
Chen
S
,
Renal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton organization in podocytes
.
PLoS One
.
2015
;
10
(
11
):
e0142291
.
6.
Lee
BT
,
Ahmed
FA
,
Hamm
LL
,
Teran
FJ
,
Chen
CS
,
Liu
Y
,
Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease
.
BMC Nephrol
.
2015
;
16
:
77
. .
7.
Briffa
JF
,
McAinch
AJ
,
Poronnik
P
,
Hryciw
DH
.
Adipokines as a link between obesity and chronic kidney disease
.
Am J Physiol Renal Physiol
.
2013
;
305
(
12
):
F1629
36
. .
8.
Ohashi
K
,
Iwatani
H
,
Kihara
S
,
Nakagawa
Y
,
Komura
N
,
Fujita
K
,
Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice
.
Arterioscler Thromb Vasc Biol
.
2007
;
27
(
9
):
1910
7
. .
9.
Udi
S
,
Hinden
L
,
Ahmad
M
,
Drori
A
,
Iyer
MR
,
Cinar
R
,
Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease
.
Br J Pharmacol
.
2020
;
177
(
1
):
110
27
. .
10.
Navarro-Diaz
M
,
Serra
A
,
Lopez
D
,
Granada
M
,
Bayes
B
,
Romero
R
.
Obesity, inflammation, and kidney disease
.
Kidney Int Suppl
.
2008
(
111
):
S15
8
.
11.
Briones
AM
,
Nguyen Dinh Cat
A
,
Callera
GE
,
Yogi
A
,
Burger
D
,
He
Y
,
Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction
.
Hypertension
.
2012
;
59
(
5
):
1069
78
. .
12.
Abella
V
,
Scotece
M
,
Conde
J
,
Gómez
R
,
Lois
A
,
Pino
J
,
The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases
.
Biomarkers
.
2015
;
20
(
8
):
565
71
. .
13.
Lee
MW
,
Lee
M
,
Oh
KJ
.
Adipose tissue-derived signatures for obesity and type 2 diabetes: adipokines, batokines and microRNAs
.
J Clin Med
.
2019
;
8
(
6
):
854
. .
14.
Williams
DM
,
Nawaz
A
,
Evans
M
.
Renal outcomes in type 2 diabetes: a review of cardiovascular and renal outcome trials
.
Diabetes Ther
.
2020
;
11
(
2
):
369
86
. .
15.
Martin
WP
,
Docherty
NG
,
Le Roux
CW
.
Impact of bariatric surgery on cardiovascular and renal complications of diabetes: a focus on clinical outcomes and putative mechanisms
.
Expert Rev Endocrinol Metab
.
2018
;
13
(
5
):
251
62
. .
16.
Nair
M
,
Martin
WP
,
Zhernovkov
V
,
Elliott
JA
,
Fearon
N
,
Eckhardt
H
,
Characterization of the renal cortical transcriptome following Roux-en-Y gastric bypass surgery in experimental diabetic kidney disease
.
BMJ Open Diabetes Res Care
.
2020
;
8
(
1
):
e001113
. .
17.
Morales
E
,
Porrini
E
,
Martin-Taboada
M
,
Lima
SL
,
Vila-Bedmar
R
,
González de Pablos
I
,
Renoprotective role of bariatric surgery in patients with established CKD
.
Clin Kidney J
.
2020
. .
18.
Mori
MA
,
Ludwig
RG
,
Garcia-Martin
R
,
Brandão
BB
,
Kahn
CR
.
Extracellular miRNAs: from biomarkers to mediators of physiology and disease
.
Cell Metab
.
2019
;
30
(
4
):
656
73
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.